Selective Estrogen Receptor Modulators
-
Subject Areas on Research
-
27-Hydroxycholesterol, an Endogenous SERM, and Risk of Fracture in Postmenopausal Women: A Nested Case-Cohort Study in the Women's Health Initiative.
-
27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
-
27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
-
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
-
Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
-
Breast cancer. Clinical practice guidelines in oncology.
-
Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM.
-
Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis.
-
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
-
Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting.
-
Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
-
Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
-
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
-
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
-
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
-
Elucidation of the molecular mechanism of action of selective estrogen receptor modulators.
-
Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.
-
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
-
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
-
From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
-
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
-
Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
-
Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.
-
Managing menopause.
-
Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators.
-
Mining the complexities of the estrogen signaling pathways for novel therapeutics.
-
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
-
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
-
Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
-
Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay.
-
Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.
-
Relationship between tamoxifen use and high risk endometrial cancer histologic types.
-
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
-
Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis.
-
Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen.
-
Structural basis for an unexpected mode of SERM-mediated ER antagonism.
-
Tamoxifen Improves Glucose Tolerance in a Delivery-, Sex-, and Strain-Dependent Manner in Mice.
-
Targeting mutant estrogen receptors.
-
Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
-
Testing whether decision aids introduce cognitive biases: results of a randomized trial.
-
The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.
-
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.
-
The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.
-
The molecular determinants of estrogen receptor pharmacology.
-
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
-
The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.
-
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
-
Use of alternative therapies in menopause.
-
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
-
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Halabi, Susan,
Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Pharmacology & Cancer Biology